Alpha Fusion partners with Curadh MTR for global development of Astatine-211 based radiopharmaceuticals

Rocket Pharmaceuticals receives FDA clearance for gene therapy targeting BAG3-associated dilated cardiomyopathy

argenx advances ARGX-119 to registrational study for congenital myasthenic syndromes

hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results

Sanofi's riliprubart receives orphan drug designation in Japan for CIDP

HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer

Sobi's Gamifant (emapalumab-lzsg) receives US FDA approval to treat macrophage activation syndrome in Still's disease

Hikma Pharmaceuticals USA announces USD1bn of new US investment

UCB reports positive Phase 3 results for fenfluramine in CDKL5 deficiency disorder

WuXi AppTec's Nantong site receives 2025 Architizer A+Award

MGI partners with Negedia to enhance genomic sequencing in Italy

Speranza Therapeutics partners with Sunshine Labs for harm reduction solutions

CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator

BioCity's SC0062 receives Chinese Breakthrough Therapy Designation for diabetic kidney disease with albuminuria

Galderma launches two phase II trials for nemolizumab in systemic sclerosis and chronic pruritus of unknown origin